MedTrace Logo

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

NCT01169714 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-01-20

No results posted yet for this study

Summary

This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.

Conditions

  • Healthy

Interventions

DRUG

0.1 mg PF-04995274

0.1 mg PF-04995274, qd, for 14 days or placebo

DRUG

1 mg PF-04995274

1 mg PF-04995274, qd, for 14 days or placebo

DRUG

10 mg PF-04995274

10 mg PF-04995274, qd, for 14 days or placebo

DRUG

15 mg PF-04995274

15 mg PF-04995274, qd, for 14 days or placebo

DRUG

1.0 mg PF-04995274

1.0 mg PF-04995274, qd, for 14 days or placebo

DRUG

15 mg PF-04995274

15 mg PF-04995274, qd, for 14 days or placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01169714 on ClinicalTrials.gov